PRMT5 and lung carcinoma: We investigated whether GSK591, a specific inhibitor of PRMT5, could control KLF5 expression and proliferation in lung cancer cells, as PRMT5 has emerged as a promising therapeutic target for cancer treatment, and several specific small‐molecule inhibitors of PRMT5 have been developed.